<code id='25D3DF54A0'></code><style id='25D3DF54A0'></style>
    • <acronym id='25D3DF54A0'></acronym>
      <center id='25D3DF54A0'><center id='25D3DF54A0'><tfoot id='25D3DF54A0'></tfoot></center><abbr id='25D3DF54A0'><dir id='25D3DF54A0'><tfoot id='25D3DF54A0'></tfoot><noframes id='25D3DF54A0'>

    • <optgroup id='25D3DF54A0'><strike id='25D3DF54A0'><sup id='25D3DF54A0'></sup></strike><code id='25D3DF54A0'></code></optgroup>
        1. <b id='25D3DF54A0'><label id='25D3DF54A0'><select id='25D3DF54A0'><dt id='25D3DF54A0'><span id='25D3DF54A0'></span></dt></select></label></b><u id='25D3DF54A0'></u>
          <i id='25D3DF54A0'><strike id='25D3DF54A0'><tt id='25D3DF54A0'><pre id='25D3DF54A0'></pre></tt></strike></i>

          Home / knowledge / comprehensive

          comprehensive


          comprehensive

          author:hotspot    Page View:5939
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In